Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
Revolution Medicines’ Acquisition of EQRx
PROCEPT BioRobotics’ $172.5 Million Common Stock Offering
Latham & Watkins advised PROCEPT BioRobotics, and Shearman & Sterling advised the underwriters. PROCEPT BioRobotics Corporation announced a follow-on offering of 5,085,494 shares of common stock at...
Korro Bio and Frequency Therapeutics’ Merger Agreement
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
RadNet’s $259.2 Million Common Stock Public Offering
Sheppard Mullin represented RadNet, and Latham & Watkins represented the underwriters. RadNet, Inc. (NASDAQ: RDNT) has announced the closing of its underwritten public offering of 8,711,250 shares...
Bunge Limited’s Business Combination With Viterra
Homburger, Latham & Watkins, Mitrani and Tauil & Chequer Advogados associated with Mayer Brown, Conyers, Jones Day and Reed Smith advised Bunge on its business combination...
TA Associates Strategic Growth Investment in Alpha II
Latham & Watkins advises Alpha II and existing shareholder WestView Capital Partners on TA Associates strategic Growth investment. TA Associates, a leading global private equity firm,...
MultiPlan Corporation’s $160 Million Acquisition of Benefits Science
Kirkland & Ellis and Simpson Thacher served as legal counsel to MultiPlan for the transaction, while Latham & Watkins served as legal advisory to Benefits Science....
4D Molecular Therapeutics’ $120 Million Common Stock Offering
Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering. 4D Molecular Therapeutics, Inc. has announced that it priced an upsized...
Merck’s Acquisition of Prometheus Biosciences
Paul, Weiss, Rifkind, Wharton & Garrison represented Merck, Latham & Watkins represented Prometheus, Skadden represented the financial advisors on the deal. Prometheus Biosciences, Inc. have entered...
Sonoma Biotherapeutics’ Collaboration Agreement with Regeneron Pharmaceuticals
Latham & Watkins advised Sonoma Biotherapeutics on the transaction. Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a collaboration to apply their scientific and...
Revolution Medicines’ $345 Million Common Stock Public Offering
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
dbt Labs’ Acquisition of Transform Data
Latham & Watkins advised dbt Labs on the deal. dbt Labs announced that it has signed a definitive agreement to acquire Transform Data Inc. The acquisition...